Upregulated expression of ADAM17 is a prognostic marker for patients with gastric cancer

Annals of Surgery

Volumn 256, Issue 6, 2012, Pages 1014-1022

  Shou, Zhang Xuan ^a   Jin, Xue ^a   Zhao, Zhong Sheng ^a  

^a ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

ADAM17; EMMPRIN; gastric cancer; immunohistochemistry; prognosis

Indexed keywords

ADAM PROTEIN; ADAM17 PROTEIN; CD147 ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; STOMACH CANCER; SURVIVAL TIME; TISSUE MICROARRAY;

ADAM PROTEINS; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD147; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; UP-REGULATION;

EID: 84870056627     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3182592f56     Document Type: Article

References (44)

1. World Health Organization. Cancer (Fact sheet N°297). WHO web site. February 2011. Available at: http://www.who.int/mediacentre/factsheets/fs297/en/ index.html. Accessed June 14, 2011.
2. Yang L. Incidence and mortality of gastric cancer in China. World J Gastroen-terol. 2006;12:17-20.
3. Bogenrieder T, Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene. 2003;22:6524-6536.
4. Blobel CP. ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol. 2005;6:32-43.
5. Galizia G, Lieto E, Orditura M, et al. Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg. 2007;31:1458-1468.
6. Duffy MJ, McKiernan E, O'Donovan N, et al. Role of ADAMs in cancer formation and progression. Clin Cancer Res. 2009;15:1140-1144.
7. McGowan PM, Ryan BM, Hill AD, et al. ADAM-17 expression in breast cancer correlates with variables of tumor progression. Clin Cancer Res. 2007;13:2335-2343.
8. McGowan PM, McKiernan E, Bolster F, et al. ADAM-17 predicts adverse outcome in patients with breast cancer. Ann Oncol. 2008;19:1075-1081
9. Wu K, Liao M, Liu B, et al. ADAM-17 over-expression in gallbladder carcinoma correlates with poor prognosis of patients. Med Oncol. 2011;28:475-480.
10. Nabeshima K, Iwasaki H, Koga K, et al. Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol Int. 2006;56:359-367.
11. Kanekura T, Chen X, Kanzaki T. Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int J Cancer. 2002;99:520-528.
12. Caudroy S, Polette M, Nawrocki-Raby B, et al. EMMPRIN-mediated MMP regulation in tumor and endothelial cells. Clin Exp Metastasis. 2002;19:697-702.
13. Quemener C, Gabison EE, Näimi B, et al. Extracellular matrix metallopro-teinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion. Cancer Res. 2007;67:9-15.
14. Zhang L, Zhao ZS, Ru GQ, et al. Correlative studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer. Wo r l d J Gastroenterol. 2006;12:3970-3976.
15. Tang Y, Nakada MT, Kesavan P, et al. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res. 2005;65:3193-3199.
16. Jia L, Wang H, Qu S, et al. CD147 regulates vascular endothelial growth factor-A expression, tumorigenicity, and chemosensitivity to curcumin in hep-atocellular carcinoma. IUBMB Life. 2008;60:57-63.
17. Marieb EA, Zoltan-Jones A, Li R, et al. Emmprin promotes anchorage-independent growth in human mammary carcinoma cells by stimulating hyaluronan production. Cancer Res. 2004;64:1229-1232.
18. Zheng HC, Takahashi H, Murai Y, et al. Upregulated EMMPRIN/CD147 might contribute to growth and angiogenesis of gastric carcinoma: a good marker for local invasion and prognosis. Br J Cancer. 2006;95:1371-1378.
19. Gabison EE, Mourah S, Steinfels E, et al. Differential expression of extracellular matrix metalloproteinase inducer (CD147) in normal and ulcerated corneas: role in epithelio-stromal interactions and matrix metalloproteinase induction. Am J Pathol. 2005;166:209-219.
20. Lee HS, Lee HK, Kim HS, et al. Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol. 2003;200:39-46.
21. Kolev Y, Uetake H, Iida S, et al. Prognostic significance of VEGF expression in correlation with COX-2, microvessel density, and clinicopathological characteristics in human gastric carcinoma. Ann Surg Oncol. 2007;14:2738-2747.
22. Fukuoka J, Fujii T, Shih JH, et al. Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer. Clin Cancer Res. 2004;10:4314-4324.
23. Gooz M. ADAM-17: the enzyme that does it all. Crit Rev Biochem Mol Biol. 2010;45:146-169.
24. Linggi B, Carpenter G. ErbB receptors: new insights on mechanisms and biology. Trends Cell Biol. 2006;16:649-656.
25. LaMarca HL, Rosen JM. Estrogen regulation of mammary gland development and breast cancer: amphiregulin takes center stage. Breast Cancer Res. 2007;9:304.
26. Miyamoto S, Hirata M, Yamazaki A, et al. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res. 2004;64:5720-5727.
27. Zhuang S, Yan Y, Daubert RA, et al. Epiregulin promotes proliferation and migration of renal proximal tubular cells. Am J Physiol Renal Physiol. 2007;293:F219-F226.
28. Zheng X, Jiang F, Katakowski M, et al. ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation. Cancer Biol Ther. 2009;8:1045-1054.
29. Ringel J, Jesnowski R, Moniaux N, et al. Aberrant expression of a disintegrin and metalloproteinase 17/tumor necrosis factor-alpha converting enzyme increases the malignant potential in human pancreatic ductal adenocarcinoma. Cancer Res. 2006;66:9045-9053.
30. Tanaka Y, Miyamoto S, Suzuki SO, et al. Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. Clin Cancer Res. 2005;11:4783-4792.
31. Yoshimura T, Tomita T, Dixon MF, et al. ADAMs (a disintegrin and metalloproteinase) messenger RNA expression in Helicobacter pylori-infected, normal, and neoplastic gastric mucosa. J Infect Dis. 2002;185:332-340.
32. Schroeder JA, Lee DC. Transgenic mice reveal roles for TGF-alpha and EGF receptor in mammary gland development and neoplasia. J Mammary Gland Biol Neoplasia. 1997;2:119-129.
33. Shiraishi N, Sato K, Yasuda K, et al. Multivariate prognostic study on large gastric cancer. J Surg Oncol. 2007;96:14-18.
34. Kornfeld JW, Meder S, Wohlberg M, et al. Overexpression of TACE and TIMP3 mRNA in head and neck cancer: association with tumour development and progression. Br J Cancer. 2011;104:138-145.
35. Ritter CA, Perez-Torres M, Rinehart C, et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res. 2007;13:4909-4919.
36. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341-354.
37. Kakiuchi S, Daigo Y, Ishikawa N, et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet. 2004;13:3029-3043.
38. Ishikawa N, Daigo Y, Takano A, et al. Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefi-tinib among patients with advanced non-small cell lung cancers. Cancer Res. 2005;65:9176-9184.
39. Zhou BB, Peyton M, He B, et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell. 2006;10:39-50.
40. Kyula JN, Van Schaeybroeck S, Doherty J, et al. Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer. Clin Cancer Res. 2010;16:3378-3389.
41. Jin JS, Wu CY, Lin YF, et al. Higher expression of epidermal growth factor receptor is associated with extracellular matrix metalloprotease in-ducer in colorectal adenocarcinoma: tissue microarray analysis of immunos-taining score with clinicopathological parameters. Dis Markers. 2006;22:309-316.
42. Vigneswaran N, Wu J, Thevananther S, et al. Epidermal growth factor receptor (EGFR) signaling regulates EMMPRIN (extracellular matrix metallopro-teinase inducer; CD147) expression in human oral intraepithelial neoplasia (OIN) cells. Fifth AACR International Conference on Frontiers in Cancer Prevention Research, November 12-15, 2006, A97.
43. Menashi S, Serova M, Ma L, et al. Regulation of extracellular matrix metal-loproteinase inducer and matrix metalloproteinase expression by amphireg-ulin in transformed human breast epithelial cells. Cancer Res. 2003;63:7575-7580.
44. von Wasielewski R, Mengel M, Wiese B, et al. Tissue array technology for testing interlaboratory and interobserver reproducibility of immunohistochem-ical estrogen receptor analysis in a large multicenter trial. Am J Clin Pathol. 2002;118:675-682.